introduction: bone metastases are the most common cause of cancer-related pain in various primary malignant tumors, most often, breast and prostate. 188re-hydroxyethylidene diphosphonate (188re-hedp) is a new and less expensive bone seeking radiopharmaceutical with favorable physical characteristics of the radionuclide such as short half life of 16.9h, maximal β energy of 2.1 mev with a 15% γ-c...

introduction:targeted radionuclide therapy (trt) has been demonstrated to be an effective therapeutic tool in patients with disseminated bone metastasis. trt is generally performed with a single radionuclide. in this study we investigated the feasibility of combined trt with a high-energy beta emitter (153sm) and a low energy beta emitter (177lu) in wistar rats. methods: the cocktail complex of...

introduction:the use of beta emitters is one of the effective methods for palliation of bone metastasis. the risk of normal tissue toxicity should be evaluated in the bone pain palliation treatment. methods: in this study, the monte carlo simulation code mcnpx was used for simulation a bone phantom model consisted of bone marrow, bone and soft tissue. specific absorbed fractions were calculated...

   Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid (177Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, 177Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and 177LuCl3. Lu-177 chloride was obt...

   Developing new bone pain palliation agents is a mandate in handling end-stage cancer patients around the world. Possibly, Lu-177 ethylenediaminetetramethylene phosphonic acid (177Lu-EDTMP) is a therapeutic agent which can be widely used in bone palliation therapy. In this study, 177Lu-EDTMP complex was prepared successfully using synthesized EDTMP ligand and 177LuCl3. Lu-177 chloride was obt...

Objective(s): Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although 177Lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177Lu- TTHMP), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. In this study,...

Bone pain due to skeletal metastases constitutes the most common type of cancer-related pain. The management of bone pain remains challenging and is not standardized. In patients with multifocal osteoblastic metastases, systemic radiopharmaceuticals should be the preferred adjunctive therapy for pain palliation. The lack of general knowledge about radiopharmaceuticals, their clinical utility an...

Introduction:The use of beta emitters is one of the effective methods for palliation of bone metastasis. The risk of normal tissue toxicity should be evaluated in the bone pain palliation treatment. Methods: In this study, the Monte Carlo simulation code MCNPX was used for simulation a bone phantom model consisted of bone marrow, bone and soft tissue. Spe...

One month later the patient received 4.22 GBq (114 mCi) 153Samarium-EDTMP for palliation of severe bone pain. Post treatment, whole body 153Samarium scan was also a “superscan” showing very similar osseous metastases pattern to the 99mTc-MDP bone scan. Anterior and posterior whole body images 24 hours after intravenous administration of 153Sm-EDTMP demonstrate diffuse osseous metastases in a ve...